MNPR Stock Analysis: Buy, Sell, or Hold?
MNPR - Monopar Therapeutics Inc. Common Stock
$97.79
2.76 (2.90%)
▲
5d:
+11.59%
30d:
+59.63%
90d:
+76.55%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MNPR is 16.1% above its trading range ($84.22). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MNPR is 16.1% above its trading range ($84.22). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $97.79, which is considered extended relative to its 30-day fair value range of $57.40 to $84.22.
Technical Outlook: Technically, MNPR is in a uptrend. The price is approaching resistance at $100.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MNPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $113.62 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNPR is in a uptrend. The price is approaching resistance at $100.33. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MNPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $113.62 (+16.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$57.40 -
$84.22
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- BEARISH: Price significantly overextended (+16.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($113.62)
- WARNING: Recommendation downgraded due to 16.1% overvaluation
Trading Range Analysis
30-Day Trading Range
$57.40 -
$84.22
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$65.00
Resistance Level
$100.33
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-31.17
Wall Street Target
$113.62
(+16.2%)
Share & Embed Analysis
Last updated: July 02, 2026 10:41 PM ET
Data refreshes hourly during market hours. Next update: 11:41 PM
Data refreshes hourly during market hours. Next update: 11:41 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
IMCR
Immunocore Holdings Ltd |
STRONG BUY
17 analysts |
$63 | 64 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
